Management of Vulvar Intraepithelial Neoplasia

Number 509

ABSTRACT: Vulvar intraepithelial neoplasia (VIN) is an increasingly common problem, particularly among women in their 40s. The term VIN is used to denote high-grade squamous lesions and is subdivided...

The Role of the Obstetrician Gynecologist in the Early Detection of Epithelial Ovarian Cancer

Number 477

(Replaces No. 280, December 2002)

ABSTRACT: Epithelial ovarian cancer is most commonly detected in an advanced stage, when the overall 5-year survival rate is 20–30%. Detection of early-stage ovarian cancer results in improved surviv...

Human Papillomavirus Vaccination

Number 467

(Replaces No. 344, September 2006)

ABSTRACT: The U.S. Food and Drug Administration has approved both a bivalent and quadrivalent human papillomavirus (HPV) vaccine. The Advisory Committee on Immunization Practices has recommended that...

Cervical Cancer in Adolescents - Screening Evaluation and Management

Number 463

ABSTRACT: Based on several recent studies, new guidelines for initiation of cervical cancer screening have been developed. Evidence shows that screening before the age of 21 years does not change the...

Aromatase Inhibitors in Gynecologic Practice

Number 412

(Reaffirmed 2012)

ABSTRACT: Aromatase inhibitors appear to be effective as an adjuvant treatment for early-stage and late-stage breast cancer. Their role in chemoprevention of breast cancer in high-risk patients remai...

Intraperitoneal Chemotherapy for Ovarian Cancer

Number 396

(Reaffirmed 2010 )

ABSTRACT: Postoperative intravenous (IV) chemotherapy for advanced stage ovarian cancer has been the standard treatment. Recent studies have found significant survival advantages with the use of adju...

Tamoxifen and Uterine Cancer

Number 336

(Reaffirmed 2008, Replaces No. 232, April 2000)

ABSTRACT: Tamoxifen may be associated with endometrial proliferation, hyperplasia, polyp formation, invasive carcinoma, and uterine sarcoma. Any symptoms of endometrial hyperplasia or cancer reported...